GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inari Medical Inc (NAS:NARI) » Definitions » Altman Z2-Score

Inari Medical (Inari Medical) Altman Z2-Score : 3.18 (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inari Medical Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Inari Medical has a Altman Z2-Score of 3.18, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Inari Medical's Altman Z2-Score or its related term are showing as below:

NARI' s Altman Z2-Score Range Over the Past 10 Years
Min: 0.95   Med: 9.69   Max: 21.12
Current: 3.18

During the past 6 years, Inari Medical's highest Altman Z2-Score was 21.12. The lowest was 0.95. And the median was 9.69.


Inari Medical Altman Z2-Score Historical Data

The historical data trend for Inari Medical's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inari Medical Altman Z2-Score Chart

Inari Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z2-Score
Get a 7-Day Free Trial 0.95 21.12 7.79 9.15 3.69

Inari Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.87 9.50 9.50 3.69 3.18

Competitive Comparison of Inari Medical's Altman Z2-Score

For the Medical Devices subindustry, Inari Medical's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inari Medical's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Inari Medical's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Inari Medical's Altman Z2-Score falls into.



Inari Medical Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Inari Medical's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.2225+3.26*-0.1098+6.72*-0.0157+1.05*2.0845
=3.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was $661.8 Mil.
Total Current Assets was $233.3 Mil.
Total Current Liabilities was $86.0 Mil.
Retained Earnings was $-72.7 Mil.
Pre-Tax Income was -16.087 + -3.174 + 5.59 + 3.024 = $-10.6 Mil.
Interest Expense was -0.078 + -0.069 + -0.043 + -0.044 = $-0.2 Mil.
Total Liabilities was $214.5 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(233.313 - 86.037)/661.776
=0.2225

X2=Retained Earnings/Total Assets
=-72.688/661.776
=-0.1098

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-10.647 - -0.234)/661.776
=-0.0157

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(447.23 - 0)/214.546
=2.0845

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Inari Medical has a Altman Z2-Score of 3.18 indicating it is in Safe Zones.


Inari Medical  (NAS:NARI) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Inari Medical Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Inari Medical's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Inari Medical (Inari Medical) Business Description

Traded in Other Exchanges
Address
6001 Oak Canyon, Suite 100, Irvine, CA, USA, 92618
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism. The company generates revenue from the sale of ClotTriever and FlowTriever systems directly to hospitals located in the United States. Majority of revenue is generated from FlowTriever system.
Executives
William Hoffman director, officer: President and CEO C/O INARI MEDICAL, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Mitch C. Hill, officer: Chief Financial Officer 1009 TENNYSON DRIVE, SOUTHLAKE TX 76902
Andrew Hykes officer: Chief Operating Officer C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Thomas Tu officer: Chief Medical Officer C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Donald B Milder director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert Keith Warner director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Catherine M. Szyman director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Cynthia L Lucchese director 7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Rebecca Chambers director 3052 ORCHARD DR., SAN JOSE CA 95134
Jonathan D Root director 2735 SAND HILL ROAD, MENLO PARK CA 94025
Cooperatieve Gilde Healthcare Iv U.a. 10 percent owner NEWTONLANN 51, UTRECHT P7 3508AB
Kirk G. Nielsen director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Gilde Healthcare Iv Management B.v. 10 percent owner NEWTONLAAN 91, UTRECHT P7 3584 BP
Gilde Healthcare Holding B.v. 10 percent owner NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB